Vaxcyte Accelerates VAX-31 Development: Phase 3 Progress and Infant Trial Completion

failed_dev_successful_ape · 2026-03-04T10:12:58+00:00

Vaxcyte, Inc. has advanced its vaccine candidate VAX-31 into Phase 3 trials for adults and infants, aiming to provide broader protection against pneumococcal disease. The company is also developing additional vaccines and expanding manufacturing, while managing significant financial losses.

failed_dev_successful_ape

2026-03-04 10:12:58

Abstract generation in progress

Vaxcyte, Inc. (PCVX) has announced significant milestones in its vaccine pipeline, with its flagship VAX-31 candidate advancing through Phase 3 clinical trials in adults while completing enrollment in infant studies. This 31-valent pneumococcal conjugate vaccine represents a comprehensive approach to preventing invasive pneumococcal disease and pneumonia, offering broader serotype coverage than any competing vaccine currently in development.

Leading Pneumococcal Vaccine Advances Through Late-Stage Trials

The Phase 3 program for VAX-31 encompasses three pivotal studies—OPUS-1, OPUS-2, and OPUS-3—each enrolling thousands of participants to assess safety, tolerability, and immune response relative to established treatments including Prevnar 20 and Capvaxine. The FDA has granted Breakthrough Therapy Designation for the adult indication, accelerating the regulatory pathway.

Clinical data timelines indicate that OPUS-1 topline results are scheduled for Q4 2026, with outcomes from the remaining two trials anticipated in the first half of 2027. In parallel, the company has completed enrollment in its Phase 2 infant dose-finding study, with preliminary findings expected in H1 2027.

Expanding Clinical Portfolio Beyond VAX-31

Vaxcyte is simultaneously progressing several next-generation vaccine candidates. VAX-24, a 24-valent formulation for infants in Phase 2 development, aims to provide enhanced coverage compared to marketed infant vaccines. The company is also developing VAX-XL, an advanced-generation vaccine utilizing carrier-sparing conjugation technology to further expand serotype protection.

Beyond pneumococcal indications, the pipeline includes VAX-A1, a novel Group A Streptococcus vaccine with Phase 1 studies scheduled to commence in 2026, and VAX-GI, a preclinical candidate targeting Shigella infections.

Manufacturing Expansion Supports Commercialization Plans

Vaxcyte concluded 2025 with $2.4 billion in cash, cash equivalents, and investments. The company reported a net loss of $246.5 million for Q4 2025, compared to $137.1 million in the prior year quarter, with the full-year loss reaching $766.6 million versus $463.9 million in 2024.

During 2025, Vaxcyte invested $335.4 million—including $21.8 million in Q4—in constructing a dedicated manufacturing facility with Lonza. The buildout was completed in Q1 2026 within the projected $350 million budget and is positioned to support global commercialization of the company’s vaccine programs.

Market activity reflects investor interest in the company’s progress, with PCVX shares trading between $27.66 and $83.33 over the past twelve months.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.